Alvotech (ICE:ALVO)
674.00
+64.00 (10.49%)
At close: Dec 5, 2025
Alvotech Revenue
Alvotech had revenue of $113.86M USD in the quarter ending September 30, 2025, with 10.56% growth. This brings the company's revenue in the last twelve months to $573.35M, up 45.55% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$573.35M
Revenue Growth
+45.55%
P/S Ratio
3.15
Revenue / Employee
$566.55K
Employees
1,012
Market Cap
219.28B ISK
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Marel | 250.20B |
| Íslandsbanki | 62.96B |
| Arion banki | 61.68B |
| Sildarvinnslan Hf. | 43.52B |
| Brim hf. | 58.07B |
| Hagar | 177.12B |
| Kvika banki | 15.14B |
| Festi | 147.75B |
Alvotech News
- 14 hours ago - ROSEN, LEADING INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO - Newsfile Corp
- 1 day ago - Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO - Business Wire
- 3 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - PRNewsWire
- 11 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewsWire
- 12 days ago - Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area - GlobeNewsWire
- 15 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO - PRNewsWire
- 16 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 16 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire